Elderly patients ( age 70 years , ECOG performance Status 0-1 ) with advanced non-small-cell lung cancer were randomized to receive docetaxel 20 mg/m ( 2 ) plus cisplatin 25 mg/m ( 2 ) on Day 1 , 8 and 15 ( docetaxel plus cisplatin ) or docetaxel 25 mg/m ( 2 ) on the same schedule ( docetaxel ) .